The following Life Sciences practice note Produced in partnership with Andrew Bowler of Bristows and Adrian Chew of Bristows provides comprehensive and up to date legal information covering:
Second (and subsequent) medical use patent claims are specific to the pharmaceutical/biotechnology industry and are used to define the scope of an invention by way of a specified medical use. For an introduction to these and other types of patent claims, see Practice Note: Major types of patent claims.
There are two different types of second medical use claim which are described in more detail below. The inclusion of a medical use as a feature in a claim has implications for the claim’s patentability and its scope of protection.
To understand the background of second medical use claims it must be appreciated that they came about under the previous 1973 version of the European Patent Convention (EPC 1973) which has since been succeeded by the EPC 2000.
The original second medical use claims granted by the European Patent Office (EPO) from the mid-1980s until 2010 followed the format of ‘the use of a product [X] in the manufacture of a medicament for a therapeutic use [Y]’, and are termed 'Swiss-type' claims. They were therefore process claims that came about to avoid two underlying problems with the patentability of a new use of a known active pharmaceutical ingredient:
that the active pharmaceutical ingredient (product) being claimed was not in of itself new as required under European patent law; and
methods for treatment of the
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
The Public Private Partnership (PPP) models are a popular way for governments to involve private investment, expertise and risk in procuring infrastructure, with the potential to deliver a project more efficiently and economically. One of the most popular PPP models for procuring infrastructure
What is rescission of a contract?The remedy of rescission is available to a party whose consent, in entering into a contract, has been invalidated in some way:•the effect of rescinding a contract is to extinguish it and restore the parties to their pre-contractual positions•the main grounds of
BREXIT: As of 31 January 2020, the UK is no longer an EU Member State, but has entered an implementation period during which it continues to be treated by the EU as a Member State for many purposes. As a third country, the UK can no longer participate in the EU’s political institutions, agencies,
There may be times when, rather than assigning the benefit of an agreement to a third party, the original parties wish instead to end their obligations to each other under that agreement and, in effect, recreate it, with the third party stepping into the shoes of one of the original parties. This is
0330 161 1234
To view our latest legal guidance content,sign-in to Lexis®PSL or register for a free trial.